A plant proteinase inhibitor from Crataeva tapia (CrataBL) attenuates elastase-induced pulmonary inflammatory, remodeling, and mechanical alterations in mice  by Oliva, Leandro V. et al.
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a  b  s  t  r  a  c  t
Chronic  obstructive  pulmonary  disease  (COPD)  can  lead  to  chronic  and  obstructive  bronchitis  and  emphy-
sema resulting  in  decreased  bronchial  lumen  size.
This  study  evaluated  the  effect  of  CrataBL,  a protein  isolated  from  the  bark  of  Crataeva  tapia,  on  lung
mechanics,  inﬂammation,  and  remodeling  after  elastase-induced  pulmonary  alterations  in  mice.
The use of CrataBL  led to  decreased  mechanical  alterations,  alveolar  septum  disruption  (Lm),  number
of  macrophage  and  neutrophil  cells in  the BALF,  and  TNF-,  MMP-9,  MMP-12,  TIMP-1,  eNOS,  and  iNOS
positive  cells  in  the  airways  and  alveolar  walls  compared  to the  animals  in the  ELA  group.  Moreover,  aOPD
rataBL
roteinase inhibitor
ulmonary emphysema
ulmonary parenchyma
reduction  in MUC-5-positive  cells  in the  airway  walls  was observed.  In conclusion,  CrataBL  attenuates
changes  in lung  mechanics,  inﬂammation,  extracellular  lung  remodeling,  and  oxidative  stress  responses
induced  by  the  administration  of elastase  and  decreased  the  volume  fraction  of isoprostane,  collagen,
and elastic  ﬁbers  in  the  airways  and  alveolar  walls  compared  to  the  animals  in  the  ELA  groups.  Therefore,
CrataBL  is  a potential  therapeutic  tool  in  the  treatment  of COPD.
©  2015  Elsevier  Ltd.  All  rights  reserved.. Introduction
Chronic obstructive pulmonary disease (COPD) is an inﬂamma-
ory disease that can induce chronic changes in the bronchi (chronic
nd obstructive bronchitis) and lung parenchyma (emphysema)
eading to structural changes and decreased bronchial lumen size.
he destruction of lung parenchyma causes the loss of alveolar
ngagement in the small airways and decreases lung elastic recoil
1,2].
Inﬂammation affects the large and small airways resulting in
oblet cell hyperplasia, increased mucous glands, and inﬁltration
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359-5113/© 2015 Elsevier Ltd. All rights reserved.of neutrophils, macrophages, and CD8-positive lymphocytes in the
upper airways, especially in the later stages of COPD. Inﬂammatory
inﬁltrates are also found in small airways, with a predominance
of macrophages in the early stages of the disease [3]. Activated
macrophages release IL-8, LTB4, tumor necrosis factor  (TNF-
), monocyte chemotactic peptide (MCP1), and enzymes such as
elastase, cathepsins (B, K, L and S), and matrix metalloproteinases
(MMP-2, -9 and -12) that act as mediators and effectors of lung
injury [4]. MMPs  selectively degrade components of the extracel-
lular matrix and play a crucial role in the trafﬁcking of inﬂammatory
cells. Imbalance in these enzymes and their inhibitors leads to dis-
eases resulting from the destruction of connective tissue [2,5,6]
and stimulate the search for alternative compounds, particularly
those from natural sources, which block uncontrolled proteolytic
activity and may  suppress the cellular signaling pathway activation
[7–11]. The increasing number of deaths [2] caused by pulmonary
diseases and the economic burden from treatments and loss of
productivity in affected patients vindicate the search for qualiﬁed
therapeutic drugs or biomarkers for early diagnosis [12]. CrataBL is
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 bifunctional glycoprotein isolated from the bark of Crataeva tapia,
hich presents lectin activity and inhibits trypsin (Kiapp 43 M)  and
he factor Xa (Kiapp 8.2 M).  CrataBL does not interfere in the activ-
ty of human plasma kallikrein, tissue kallikrein, human neutrophil
lastase, plasmin, or chymotrypsin [11]. However, previous studies
ave shown that CrataBL binds to glycosaminoglycans (negatively
harged compounds bound to cell surfaces) [13,14], particularly to
eparin [15], and is effective in neutralizing heparin’s anticoagula-
ion activity [11,16].
This study evaluated the effect of CrataBL in elastase-induced
ulmonary inﬂammatory, remodeling, and mechanical alterations
n mice with emphysema. We  evaluated respiratory mechanics and
nﬂammatory, remodeling, and oxidative stress markers in airways
nd alveolar walls.
. Materials and methods
.1. Plant protein
CrataBL was puriﬁed following the methodology described by
erreira et al. [11]. The concentration of the lectin/inhibitor used
as determined by the Lowry assay; the dose used (2 mg/kg) was
he same as that reported for BbCI, another proteinase inhibitor
17].
.2. Animals
Thirty-two C57Black/6 young adult male mice (20–25 g)
btained from the University of São Paulo were used in the study.
he 6–8 weeks old animals were held in the laboratory vivarium
or 2 weeks prior to the study start. The study was approved by the
thics Committee for Analysis of Research Projects (CAPPesq) of the
linical Hospital and Faculty of Medicine at the University of São
aulo. The animals were handled in accordance with the guidelines
or the care of laboratory animals [18].
.3. Animal model
The animals were randomly divided into four groups. 1. Elas-
ase group (ELA) – The animals were anesthetized with isoﬂurane
nd the neck region was shaved and disinfected with povidone
here an incision of approximately 0.5 cm was  made in the mid-
egion to expose the trachea. Using a 30-unit syringe, a single 50 l
ose of 0.025 mg  of porcine pancreatic elastase (Sigma, CA, USA)
as injected directly into the trachea between the cartilaginous
ings using a 30-unit syringe and a single 50 l dose of 0.025 mg
f porcine pancreatic elastase (Sigma, CA, USA. The wound was
utured, and the neck area was disinfected with povidone. 2. Elas-
ase group treated with CrataBL (ELA-CrataBL) – CrataBL (2 mg/kg)
as injected intraperitoneally (i.p.) one hour after the intratra-
heal administration of elastase (0.025 mg  in 50 l). After 14 days,
he animals received two doses of CrataBL (2 mg/kg) every seven
ays (n = 8). Control group (SAL) – Saline was injected intraperi-
oneally (i.p.) one hour after the intratracheal administration of
aline (50 l). After 14 days, the animals received two  doses of
aline every seven days (n = 8). Control group treated with CrataBL
SAL-CrataBL) – CrataBL (2 mg/kg) was injected intraperitoneally
ne hour after the intratracheal administration of saline (50 l).
fter 14 days, the animals received two doses of CrataBL (2 mg/kg)
very seven days (n = 8).
.4. Mechanical evaluationTwenty-eight days after the study start, the animals were anes-
hetized with thiopental (250 mg/kg i.p.) and tracheotomized. A
etal cannula was inserted through the tracheostomy hole andistry 50 (2015) 1958–1965 1959
ﬁxed with cotton thread around the trachea. The animals were
connected to a mechanical ventilator for small animals (FlexiVent,
Scireq,  Montreal, Canada) and ventilated with a tidal volume of
10 ml/kg at a respiratory rate of 120 cycles/min and inspiratory
ﬂow with a sine curve. To induce skeletal muscle relaxation during
ventilation, the animals received 0.2 mg/kg pancuronium intraperi-
toneally. Data recording began when the animal was  still. With the
expiratory valve in the closed position, signal producing oscilla-
tions of different frequencies of airﬂow material (0.25 to 19.625)
for 16 s were applied. The desired pressure values were obtained
and impedance in the airway (pressure/ﬂow) was calculated as a
function of different frequencies.
Using a pop-up signal of 75% in 16 s, 3 blocks of 8 s were used to
calculate the parameters of mechanical oscillation (i) according to
the equation:
Z(f ) = Raw + i(2f )law + [Gtis − iHtis]
(2f )˛
In this model, Z(f) is the impedance of air as a function of
frequency, i is the imaginary unit (−1½), f is the frequency, law
is the inertance of airways, and  ˛ = (2/)  × arctan (Htis/Gtis). The
obtained parameters were Raw (airway resistance), Gtis (lower
airway or tissue resistance), and Htis (lung tissue elastance).
2.5. Determination of exhaled nitric oxide (ENO)
During the mechanical ventilation, gas was collected at the expi-
ratory portion of the fan through a balloon impermeable to NO
(Mylar bag, Sievers, Instruments Inc., Boulder, CO,  USA) for 5 min.
After the collection period, the balloons were sealed for later anal-
ysis.
Nitric oxide was  measured by a chemiluminescence analyzer
(280 NOA – Nitric Oxide Analyzer – Sievers Instruments Inc., Boul-
der, CO, USA). The average concentration of NO was recorded in
parts per billion (ppb) as an index of NO concentration in exhaled
air.
2.6. Fluid analysis (BALF)
BALF was  performed by injecting 1.5 ml of saline (3 × 0.5 ml)
through a tracheal cannula. The total number of cells obtained in
the lavage was  determined using a Neubauer chamber. The cells
were differentially counted using a cytospin preparation followed
by staining with Quick-Stain reagent. Differential cell counts were
performed by evaluating more than 300 cells in an optical micro-
scope.
2.7. Morphometric study
The animals were exsanguinated, the chest was opened, and
the heart and lungs were removed en bloc. The lungs were ﬁxed
with 4% formaldehyde at a constant pressure of 20 cm H2O for
48 h to homogenize the distension of the pulmonary parenchyma
and subsequently stored in 10% formalin for up to 7 days. Lungs
were cut on the long axis and subjected to histological processing;
slides were stained with Hematoxylin–Eosin, Resorcin–Fuchsin (for
the analysis of elastic ﬁbers), and Picrosirius (for the analysis of
collagen ﬁbers). Additional slides were also prepared for immuno-
histochemical staining for the analyses on expression of MMP-9,
MMP-12, TIMP-1, MUC-5, iNOS, eNOS, and 8-iso-PG2F.
The morphometric analysis was  performed in an optical micro-
scope using a lattice of lines and points (50 lines and 100 points)
according to the technique of point counting [19]. We  analyzed 20
ﬁelds of lung parenchyma. The results were expressed as percent-
ages of positive areas (volume ratio) [20].
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Table 1
Bronchoalveolar lavage ﬂuid analysis.
Broncoalveolar lavage Groups (n = 8)
SAL ELA SAL-CrataBL ELA-CrataBL
Total cells (cells/104 m2) 0.5 ± 0.2 2.8* ± 0.4 0.7 ± 0.1 1.5** ± 0.1
Macrophages (cells/104m2) 0.63 ± 0.04 1.47 ± 0.2 0.7 ± 0.1 1.46 ± 0.09
Neutrophils (cells/104m2) 0.0007 ± 0.0007 0.50* ± 0.17 0.003 ± 0.001 0.04 ± 0.01
Lymphocytes (cells/104m2) 0.0017 ± 0.0007 0.26* ± 0.009 0.003 ± 0.001 0.02 ± 0.004
Eosinophils (cells/104m2) 0.0000 ± 0.0000 0.05* ± 0.001 0.005 ± 0.001 0.001 ± 0.005
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* p < 0.05 compared to other groups.
** p < 0.05 compared to the SAL and SAL-CrataBL groups.
The reticle was coupled, adjacent to the wall of the airway from
he base of the epithelium, for the evaluation of airways. Three to
ve airways were randomly selected for evaluation in each ani-
al, and approximately three ﬁelds per airway were assessed. This
echnique was used to count neutrophils, positive cells for TNF-,
MP-9, MMP-12, TIMP-1, MUC-5, eNOS, and iNOS, and to evaluate
he volume fraction of isoprostane, collagen, and elastic ﬁbers.
.8. Mean alveolar diameter (Lm)
The alveolar diameter analysis was performed using a micro-
cope with an appropriate reticulum to calculate the mean alveolar
iameter. The initial area of the lung parenchyma was  determined,
xcluding vessels and airways. A lattice with 50 straight (100
oints) lines was placed over the lung parenchyma area, and point
ntersections were counted in the alveolar wall. The mean alveolar
iameter was calculated according to the ratio between the lung
arenchyma area and number of intersections between the lines
nd lung parenchyma.
.9. Immunohistochemistry
Lung sections were deparafﬁnized and rehydrated. Step 1 –
ecovery of Antigen: Sections were treated with Proteinase K for
0 min  (37 ◦C) followed by 20 min  at room temperature; slides were
ashed in PBS. Step 2 – Blocking and Incubation with Primary Anti-
ody: Endogenous peroxidases were blocked by incubation in 3%
ydrogen peroxide (10 v% H2O2) (3 × 10 min). This was  followed
y incubation with primary antibodies, which were applied to sec-
ions of experimental and control tissues (positive and negative);
lides were incubated overnight. Step 3 – Incubation with Secondary
ntibody and Peroxidase Complex: The slides were washed in PBS
nd incubated with secondary antibody using an ABC Kit by Vecta-
tain (Vector Elite-PK-6105 (anti-goat)/PK-6101 (anti-rabbit). Step
 – Visualization: The slides were washed in PBS and proteins were
isualized using 3,3 diaminobenzidine chromogen (DAB) (Sigma
able 2
ffect of CrataBL treatment on positive cells in inﬂammation and lung remodeling in alve
Groups (n = 8)
SAL 
Inﬂammatory response
Macrophages (cells/104 m2) 11.75 ± 0.75 
Neutrophils (cells/104 m2) 0.43 ± 0.05 
TNF-  positive cells (cells/104 m2) 3.11 ± 0.13 
Extracellular remodeling markers
Collagen ﬁbers (%) 9.4 ± 0.1 
Elastic  ﬁbers (%) 0.3 ± 0.03 
MMP-9  positive cells (cells/104 m2) 6.65 ± 0.70
MMP-12  positive cells (cells/104 m2) 10.12 ± 0.83 
TIMP-1  positive cells (cells/104 m2) 3.63 ± 0.59 
ata are presented as the mean ± SEM.
p < 0.05 or **p  < 0.05 represent signiﬁcant differences compared to controls.Chemical Co., St. Louis, MI,  USA). Step 5 – Counter-Staining and
Mounting of Slides: The slides were thoroughly washed in tap water
and counter-stained with Harris Hematoxylin (Merck, Darmstadt,
Germany); slides were subsequently washed in water, dehydrated,
diaphanized, and mounted using the Entellan microscopy resin
(Merck, Darmstadt, Alemanha).
The following primary antibodies were used: anti-mouse
macrophage Mac2 (Cedarlane Lab, Ontario, Canada, 1:60,000);
anti-mouse neutrophils (AbDSerotec, Kidlington, UK; 1:400); anti-
mouse MMP-9 (Santa Cruz Biotechnology, CA; 1:500); antibody
anti-mouse MMP-12 (Santa Cruz Biotechnology, CA; 1:100);
anti-iNOS (LabVision, NeoMarkers, California; 1:500); anti-eNOS
(LabVision, NeoMarkers, CA; 1:100); anti-TIMP-1 (LabVision,
NeoMarkers, CA; 1:400); anti-TNF (Santa Cruz Biotechnology,
California, U.S.; 1:900); anti-isoprostane-8 (Oxford Biomedical
Research, Oxford, United Kingdom; 1:10.000), and anti-MUC-5
(LabVision, NeoMarkers, CA; 1:400).
2.10. Data analysis
Statistical analysis was  performed using the SigmaStat software
(SPSS Inc., Chicago, IL, USA). Multiple comparisons were made by
One-way ANOVA. The Holm–Sidak test was used for comparisons
between groups. Data are presented as mean ± standard error and
depicted in bar graphs with error bars. Signiﬁcance was considered
at p < 0.05.
3. Results
3.1. Lung mechanics
The values of respiratory system elastance (Ers) in all exper-
imental groups are shown in the Fig. 1A. Ers was signiﬁcantly
higher, as expected, in the ELA group compared to the SAL group
(53.6 ± 6.3 cm H2O ml−1 vs 37.0 ± 3.4 cm H2O ml−1, respectively;
(p < 0.05); Ers was 60.8% attenuated by the CrataBL treatment.
olar walls.
ELA SAL-CrataBL ELA-CrataBL
22.88* ± 2.24 7.86 ± 0.38 9.58** ± 1.36
1.18* ± 0.15 0.57 ± 0.06 0.75** ± 0.1
12.52* ± 0.42 4.83 ± 0.16 10.41** ± 0.49
11.5* ± 0.11 8.8 ± 0.8 10.8** ± 0.13
0.5* ± 0.03 0.3 ± 0.3 0.3** ± 0.02
18.59* ± 1.8 7.12 ± 0.71 10.35** ± 0.65
20.17* ± 1.92 7.49 ± 0.63 14.15** ± 0.59
14.42* ± 2.05 5.73 ± 1.95 9.89** ± 2.79
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Fig. 1. Mechanical evaluation. The animals were anesthetized with thiopental
(250 mg/kg i.p.) and tracheotomized twenty-eight days after the study start; the pro-
cedure was  performance as described in methods. (A) Respiratory system elastance
(Ers), (B) Respiratory system resistance (Rrs), (C) airway resistance (Raw), (D) lung
tissue elastance (Htis) and (E) Lung tissue resistance (Gtis). A signiﬁcant increase
of  the values in ELA group and a signiﬁcant decrease (*p < 0.05) in all ELA-CrataBL
groups was observed.
Fig. 2. Determination of exhaled nitric oxide (ENO). Exhaled NO was collected in
the four experimental groups 28 days after treatment. The animals treated with
CrataBL (SAL-CrataBL and ELA-CrataBL) showed a signiﬁcant reduction (**p < 0.05
and *p < 0.05) in exhaled NO compared to the groups SAL and ELA treated groups.
Besides, no signiﬁcant difference between SAL and SAL-CrataBL
were notice. The values of mechanically ventilated resistance (Rrs)
(Fig. 1B) did no differ between the CrataBL groups, but were
decreased either among the SAL or ELA groups. Considering the
effect on airway resistance (Raw) shown in Fig. 1C, the increase
of Raw provoked by elastase was  reduced by the inhibitor to the
control level. The same proﬁle was  observed in Fig. 1D for lung tis-
sue elastance (Htis) and in the Fig. 1E in the lung tissue damping
(Gtis) parameters, which signiﬁcantly decreased in the ELA-CrataBL
group compared to the ELA group (p < 0.05).
The Exhaled nitric oxide (ENO) levels are presented in Fig. 2. We
observed that ENO levels were lower in the CrataBL groups (around
31% and 73.0%) than in the untreated SAL and ELA groups, respec-
tively.
Table 1 shows the results from the bronchoalveolar lavage ﬂuid
analyses. A signiﬁcant increase in the total bronchoalveolar lavage
cell count was observed in the ELA group compared to the control
groups (SAL and SAL-CrataBL, p < 0.05). ELA-CrataBL group attenu-
ated the number of total bronchoalveolar lavage cells compared to
the ELA group (p < 0.01).
There was no difference between the number of macrophages
in the ELA and ELA-CrataBL groups. However, the increased neu-
trophils, lymphocytes, and eosinophils accumulation in the ELA
group related to the control groups was attenuated by the inhibitor
treatment (p < 0.05).
Fig. 3 shows the mean alveolar diameter values (Lm) in all
experimental groups. A signiﬁcant increase in Lm was  observed
in the ELA group (69.0 ± 2.7 m)  when compared to the control
groups; moreover, Lm is signiﬁcantly lower in the ELA-CrataBL
group (49.9 ± 3.3 m; p < 0.05).
Fig. 3. Alveolar diameter analysis (Lm). Increases in Lm were observed on the 28th
after treatment. Mean linear intercept values were measured in the experimental
groups. Elastase-induced group shows a signiﬁcant increase in the values compared
to  other groups (*p < 0.05) decreasing in the ELA-CrataBL group.
1962 L.V. Oliva et al. / Process Biochemistry 50 (2015) 1958–1965
Table 3
Effect of CrataBL on inﬂammatory and extracellular remodeling alteration in airway walls.
Groups (n = 8)
SAL ELA SAL-CrataBL ELA-CrataBL
Inﬂammatory response
Neutrophils (cells/104 m2) 0.23 ± 0.05 0.59* ± 0.10 0.26 ± 0.04 0.46** ± 0.06
TNF-  positive cells (cells/104 m2) 5.27 ± 0.34 15.82* ± 1.03 6.67 ± 1.49 14.30** ± 1.28
Extracellular remodeling markers
Collagen ﬁbers (%) 5.72 ± 0.78 8.73* ± 2.59 6.19 ± 1.87 7.80** ± 1.37
Elastic  ﬁbers (%) 0.69 ± 0.02 2.56* ± 0.18 1.14 ± 0.11 1.4** ± 0.13
MMP-9  positive cells (cells/104 m2) 7.39 ± 1.3 14.86* ± 1.77 5.64 ± 0.66 9.93** ± 1.39
MMP-12  positive cells (cells/104 m2) 12.98 ± 0.59 18.56* ± 1.79 6.99 ± 1.37 12.06* ± 1.15
TIMP-1  positive cells (cells/104 m2) 0.44 ± 0.09 1.31* ± 0.12 0.55 ± 0.07 0.73** ± 0.05
7.09* ± 1.71 1.01 ± 0.42 3.56** ± 0.54
D rences at p < 0.05, respectively compared to controls (saline and elastase).
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Fig. 4. Oxidative stress: Lung tissue from mice in the elastase-inﬂamed groupsMUC-5  positive cells (cells/104 m2) 1.31 ± 0.95 
ata are presented as the mean ± SEM * or ** represent statistically signiﬁcant diffe
.2. Inﬂammatory and remodeling responses in the alveolar and
irway walls
The inﬂammatory and remodeling indicators of alterations in
lveolar walls presented in Table 2 showed that the numbers of
acrophages, neutrophils, TNF-, MMP-9, MMP-12, and TIMP-1
ositive cells, and the volume fraction of collagen and elastic ﬁbers
n the pulmonary parenchyma, signiﬁcantly increased in the ELA
roups compared to controls. The ELA-CrataBL group showed sig-
iﬁcantly reduced values in all parameters compared to the ELA
roup (p < 0.05).
Table 3 shows inﬂammatory and remodeling indicators of alter-
tions in the airways. The numbers of neutrophils, TNF-, MMP-9,
MP-12, TIMP-1, and MUC-5 positive cells, and volume fraction of
ollagen and elastic ﬁbers signiﬁcantly increased in the airways in
he ELA group compared to the control (SAL, SAL-CrataBL groups;
 < 0.001). The ELA-CrataBL group showed signiﬁcantly decreased
alues in all parameters compared to the ELA group (p < 0.05).
.3. Evaluation of the oxidative stress in the alveolar and airway
alls
Fig. 4 shows the graphic and numbers of eNOS- (A); iNOS-
ositive cells (B), and volume fraction of isoprostane (C) in alveolar
alls. The signiﬁcant increases in eNOS- and iNOS-positive cells,
nd in the volume fraction of isoprostane observed in the ELA group
ompared to controls were suppressed by the CrataBL treatment
p < 0.001) in all comparisons. Similarly, the increased values of
hose parameters in the airways (Fig. 5) in the ELA group showed an
mportant effect attenuation in the ELA-CrataBL groups in relation
o the ELA groups (p < 0.001).
. Discussion
The involvement of proteinases in the pathophysiology of
mphysema is established [5]. However, there is still controversy
bout the type of proteinases and their speciﬁc functions that
ontribute to the development and progression of emphysema.
ecently, new therapeutic strategies for the treatment of COPD
ave been investigated aiming at the control of events related to
he activation of proteinases. The importance of a proteinase–anti-
roteinase balance in pulmonary emphysema is conﬁrmed in
atients with deﬁciency in 1-antitrypsin (an inhibitor of neu-
rophil proteinase) who show destruction in the lung parenchyma
1]. In this study, the natural compound CrataBL was applied in mice
ith emphysema resulting in a reduction in the respiratory sys-em resistance (Rrs) in animals in the ELA-CrataBL group, regardless
f the intratracheal elastase administration. This indicates a bron-
hodilator effect of the CrataBL proteinase inhibitor, which may
e tested in experimental models of asthma. In addition, the Raw
treated with saline and crataBL (SAL-CrataBL and ELA-CrataBL) for 28 days. Mean and
standard error of (A) eNOS- and (B) iNOS-positive cells in the experimental groups.
*p  < 0.001 compared to the other groups. (C) Isoprostane volume fraction mean
values and standard error, in alveolar walls, in all experimental groups. *p < 0.05
compared to other groups.
L.V. Oliva et al. / Process Biochem
Fig. 5. Oxidative stress in the airways of mice in the elastase-inﬂamed groups
treated with saline and CrataBL (SAL-CrataBL and ELA-CrataBL) for twenty-eight
days. Mean and standard error of (A) eNOS-, (B) iNOS-positive cells and (C) iso-
prostane volume fraction in the experimental groups. The ELA groups showed
s
a
t
v
t
c
t
i
g
b
i
h
T
s
m
t
aigniﬁcantly increased values (*p < 0.001) compared to the other groups and attenu-
tion (*p < 0.05) of these values were observed in the ELA-CrataBL groups compared
o  the ELA groups.
alues that were enlarged in the ELA group, diminished by 57.1% in
he ELA-CrataBL group, which suggests that the airway constriction,
aused by intratracheally administered elastase, was  controlled by
he CrataBL proteinase inhibitor.
The respiratory system elastance (Ers), which assesses changes
n distal airways and lung parenchyma, was increased in the ELA
roup demonstrating the effectiveness of the experimental model
y showing enlargement and destruction of alveoli and changes
n distal airways. These results are similar to those observed in
umans with COPD, particularly under conditions of severe disease.
hus, the evaluation of inﬂammation, remodeling, and oxidative
tress changes in the airways contributes to the understanding of
echanisms involved in the effects of CrataBL.
Tibboel and Post [21] evaluated pulmonary function in mice,
hat received the same dose of elastase (0.016 mg)  used in our study,
nd showed increased respiratory rate and tidal volume, decreasedistry 50 (2015) 1958–1965 1963
tissue elastance, and enlargement of alveolar spaces, similar to
what was  observed in our experimental model; furthermore, Crat-
aBL attenuated the destruction of lung parenchyma in mice in the
ELA group.
Scuri et al. [22] showed that elastase leads to increased pro-
duction of bradykinin by activating tissue kallikreins, which, in
turn, increases lung resistance and elastance, leading to bron-
choconstriction. These authors showed that this response is not
reversed by the treatment with a histamine antagonist although it
was efﬁciently blocked by antagonists of the bradykinin B2 recep-
tor, therefore conﬁrming the involvement of the kallikrein–kinin
system in the process. In the present study, we showed that Crat-
aBL ameliorate lung function corroborating the results obtained by
Scuri showing that the kallikrein–kinin system may be involved in
the lung function alterations observed in this model of emphysema.
The inﬂammatory response assessed by bronchoalveolar lavage
ﬂuid analyses showed a signiﬁcant decrease in the number of neu-
trophils, lymphocytes, and eosinophils in the ELA-CrataBL group
compared to the ELA group indicating an important role of Crat-
aBL as an anti-inﬂammatory protein. This result is similar to that
reported by Neuhof et al. [23] in a model of lung edema caused
by neutrophil activation, where the BbCI elastase inhibitor (from
the Kunitz family of plant inhibitors) decreased the formation of
edema. Moreover, Oliveira et al. [17] using models of inﬂammation
in animals pretreated with BbCI (an inhibitor of HLE and cathep-
sin G) conﬁrmed the main role of these enzymes in the capturing,
rolling, transmigration, and cell adhesion of inﬂammatory cells.
While not directly inhibiting the activity of HLE and cathepsin G,
CrataBL may  signiﬁcantly interfere in these processes after bind-
ing to heparin [24] and glycosaminoglycans on the cell surface.
Heparin potentiates the activity of proteases, mainly cathepsins
[25] and plasma kallikrein [26]; therefore, CrataBL may  interfere
in the generation of pro-inﬂammatory peptides such as kinins (e.g.,
bradykinin). The indirect interference in proteolytic activity also
relates to the ﬁnding that the levels of metalloproteinases are
diminished by the treatment with an inhibitor in the present study.
Carl et al. [27] showed that bradykinin increased the release of
PMN  elastase which, in turn, increased microvascular permeabil-
ity. The authors concluded that blocking the release of bradykinin
could be useful in treating inﬂammatory diseases such as COPD.
Additionally, Bhoola et al. [28] showed that neutrophils have all
the components to generate kinins, which are involved in local
inﬂammatory response and activation and migration of inﬂamma-
tory cells. Hence, there are signiﬁcant implications concerning the
pathological conditions, such as in COPD, in which the activation of
neutrophils and kallikrein–kinin occurs, reinforcing the importance
of the data obtained in the present study.
Tumor necrosis factor alpha (TNF-)  is one of the inﬂamma-
tory mediators involved in the pathophysiology of COPD [29].
Because macrophages and/or respiratory epithelial cells produce
TNF-, the anti-inﬂammatory effect of CrataBL was demonstrated
through the detection of a decreased number of macrophages in
the ELA-CrataBL group. This effect resulted in a decreased number
of TNF--positive cells and improved pulmonary function status.
The remodeling response showed increased volume fraction of
elastic and collagen ﬁbers in the ELA group. These changes were
reversed in the ELA-CrataBL group, most likely associated with
the CrataBL neutralizing action over heparin. Therefore, CrataBL
is effective in blocking the activation of proteases, including neu-
trophil elastase, and the breakdown of elastic ﬁbers located within
the lung parenchyma.
The evaluation of MMP-9 and MMP-12 showed a signiﬁcant
increase in these enzymes in the lung parenchyma and airways of
animals in the ELA group, and a signiﬁcant decrease in the ELA-
CrataBL group corroborating the observed effects of CrataBL in
blocking protease activation as mentioned above.
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In addition to having high afﬁnity for heparin, cathepsins can
ctivate pro-urokinases, which activate plasminogen to form plas-
in. In turn, plasmin mainly activates MMP-2 and MMP-9. Plasmin
lso activates elastase and further increases metalloproteinases and
athepsin activities. Thus, heparin plays an important role in ampli-
ying the network of proteinase activation in pathophysiological
rocesses [30].
We observed an increase in MMP-9 associated with an increase
n its inhibitor TIMP-1, which may  result from an attempt to repair
amages [31]. The imbalance between MMP-9 and TIMP-1 may
nterfere with cell migration and tissue repair.
The observed increased number of MUC-5-positive cells in the
LA group may  suggest a change in the airway wall that occurs
ater the development of the disease. However, it is important to
onsider that mice, unlike humans, do not have true goblet cells
32] and that washing the slides during their preparation may  also
ave contributed to clear airways mucus. Thus, we observed a slight
hange in relation to the number of MUC-5-positive cells, which
s perhaps associated with this stage of the disease or due to the
imitations of the techniques used.
We  demonstrated that the lung injury induced by intratracheal
lastase administration caused an increase in exhaled nitric oxide
hat was reduced by the CrataBL treatment. CrataBL attenuated
he oxidative stress response with a reduced number of eNOS-
nd iNOS-positive cells in the airway and alveolar walls in mice
n the ELA group. Our research group previously demonstrated the
mportant role of nitric oxide in experimental asthma [20,33] with
ncreased cellular expression of iNOS and eosinophils in the distal
irways of sensitized animals. Furthermore, our group also showed
hat nNOS-positive cells, although constitutive, were increased
mong inﬂammatory cells (eosinophils and lymphomononuclear)
33].
Regarding the response in the airway and alveolar walls from
nimals with chronic allergic inﬂammation, the iNOS inhibitors
1400W or L-NAME) attenuated the response to the antigen chal-
enge. This functional impairment was associated with the control
f inﬂammation, remodeling, and oxidative stress [20,34,35]. The
ttenuation caused by blocking the response of iNOS production
ppears to also depend on the modulation of the Rho-kinase path-
ay [36].
Thus, in the inﬂammation process, the activation of proteinases
eads to increased production of bradykinin and subsequent acti-
ation of pro-inﬂammatory cytokines, which thereby increase the
umbers of cNOS- and iNOS-positive cells. NO produced by iNOS
nd cNOS (eNOS and nNOS) leads to increased exhaled NO, which
ay  have triggered the events observed in this model [37].
As previously mentioned, CrataBL counteracted the effects of
eparin. Lakshmi et al. [38] showed that low molecular weight hep-
rin inhibits iNOS in activated conditions of injury. These results
upport the observed reduction in exhaled nitric oxide, in the ELA
roup after treatment with the CrataBL inhibitor in our study. More-
ver, Prado et al. [20] showed that iNOS inhibition reduces MMP-9,
IMP-1, and TGF-beta in vascular walls of animals sensitized with
valbumin. All these mediators affect the production of collagen
nd elastic ﬁbers contributing to extracellular matrix remodeling in
irways and vessels. The observed reduction of metalloproteinases
y CrataBL in this study and TIMP-1 in a previously reported study
33] could result from the effect of iNOS inhibition.
Surprisingly, a signiﬁcant reduction in exhaled nitric oxide was
lso associated with the SAL-CrataBL group. Thus, it is likely that
he binding of CrataBL to heparin might affect the activity of all
itric oxide synthases, not only constitutive synthases, but also
NOS that produce large amounts of NO. Moreover, it is interest-
ng to note that there was a signiﬁcant reduction in respiratory
ystem resistance (Rrs), which indicates the response in the proxi-
al  airways in animals in the ELA-CrataBL and SAL-CrataBL groupsistry 50 (2015) 1958–1965
regardless of the administration of saline or elastase (Sal-CrataBL
and ELA-CrataBL groups). The reduction in Rrs and its consequent
bronchodilator effect may  have resulted from the effect of CrataBL
on iNOS- and eNOS-positive cells. The expression of both enzymes
in the airway and alveolar walls was  signiﬁcantly reduced by the
CrataBl treatment.
Interestingly, the reduction in isoprostane PGF-2 by CrataBL,
which is due to a decrease in peroxynitrite formation [36,37], indi-
cated that the natural protein protects the cell membrane from lipid
peroxidation.
The establishment of a relationship between the different
parameters evaluated in this study is difﬁcult in in vivo studies. Crat-
aBL may  have affected these parameters in a direct or indirect way.
It is well known that elastase destroys elastic ﬁbers, and that lung
repair depends on the recruitment of inﬂammatory cells to restore
lung function. Because CrataBL reduces lung inﬂammation, it can
consequently modulate its remodeling process. Once neutrophils
were activated, they induce the release of oxidative stress and nitric
oxide. The reduction in oxidative stress could be due to a reduction
in iNOS and/or inﬂammation. The control of the MMP/TIMP balance,
induced by CrataBL, controls the remodeling process observed in
the lung of emphysematous mice. However, the reduction in lung
inﬂammation and oxidative stress can also control the remodeling
process. In fact, the relevant ﬁnding in the present study is that,
through a direct or indirect effect, CrataBL reduced lung destruc-
tion and inﬂammation as well as oxidative stress. These outcomes
probably contributed to the improved lung function observed in
CrataBL treated-animals, supporting the substantial relevance of
the present study.
5. Conclusion
In this experimental model of lung damage, induced by intra-
tracheal administration of elastase, and treatment with CrataBL, a
proteinase inhibitor, decreased lung mechanics alterations associ-
ated with a signiﬁcant reduction in exhaled nitric oxide reduced
the inﬂammatory responses in the airways and alveolar walls and
consequently attenuated the destruction of alveolar walls. Further-
more, the CrataBL treatment led to decreased levels of extracellular
remodeling markers in the alveolar and airway walls and induced
an attenuation of the oxidative stress response.
Our results show that this inhibitor may  be a potential thera-
peutic tool for the treatment of COPD. Moreover, further research
possibilities using this experimental model could contribute to the
development of therapeutics applied to asthma.
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